Immutep : Corporate Presentation -March 26, 2024 at 08:12 am EDT

Forward-Looking Statements


The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 . These slides have been...

Related Keywords

China , ,Immutep Limited ,Nasdaq ,Novartis ,First In Class Lead ,Nature Reviews Drug Discovery ,Checkpoint Discovery ,Approval Timeline ,Chief Scientific Officer ,Checkpoint Inhibitors ,Asthma Reports ,Major Histocompatibility Complex Class ,Neck Squamous Cell Carcinoma ,Non Small Cell Lung Cancer ,Breast Cancer ,Ulcerative Colitis ,Investigator Initiated Trials ,Stimulate Immune System ,Immune Effect Leading ,Positive Clinical ,Year Survival ,Combined Nivolumab ,Advanced Melanoma ,Untreated Advanced Melanoma ,Markets ,